Expression levels and significance of nuclear factor-κB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma

Digestive Surgery

Volumn 30, Issue 4-6, 2014, Pages 309-316

  Zhou, Quanbo ^a   Gong, Yuanfeng ^a   Huang, Feng ^b   Lin, Qing ^a   Zeng, Bing ^a   Li, Zhihua ^a   Chen, Rufu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor; Intrahepatic cholangiocarcinoma; Intrahepatic lithiasis; Nuclear factor B

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CHEMISTRY; DISEASE COURSE; HUMAN; INTRAHEPATIC BILE DUCT; LIVER DISEASE; LIVER TUMOR; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PRECANCER; PROGNOSIS; RETROSPECTIVE STUDY; STONE FORMATION; SURVIVAL RATE;

BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; HUMANS; LITHIASIS; LIVER DISEASES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; NF-KAPPA B; PRECANCEROUS CONDITIONS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84896261889     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000354341     Document Type: Article

References (48)

1. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125
2. Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10
3. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357
4. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT: Incidence rates of intra- And extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007; 99: 895-897
5. Von Hahn T, Ciesek S, Wegener G, et al: Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol 2011; 46: 1092-1098
6. Taylor-Robinson SD, Toledano MB, Arora S, et al: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820
7. Khan SA, Toledano MB, Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82
8. Chen MF, Jan YY, Jeng LB, et al: Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 1999; 6: 136-141
9. Kubo S, Kinoshita H, Hirohashi K, Hamba H: Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995; 19: 637-641
10. Okuda K, Nakanuma Y, Miyazaki M: Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology. J Gastroenterol Hepatol 2002; 17: 1049-1055
11. Lesurtel M, Regimbeau JM, Farges O, Colombat M, Sauvanet A, Belghiti J: Intrahepatic cholangiocarcinoma and hepatolithiasis: An unusual association in Western countries. Eur J Gastroenterol Hepatol 2002; 14: 1025-1027
12. Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K: Cholangiocarcinoma: Principles and current trends. Hepatobiliary Pancreat Dis Int 2011; 10: 10-20
13. Friman S: Cholangiocarcinoma - current treatment options. Scand J Surg 2011; 100: 30-34
14. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-?B. J Clin Invest 2001; 107: 241-246
15. Lu T, Stark GR: Cytokine overexpression and constitutive NF-?B in cancer. Cell Cycle 2004; 3: 1114-1117
16. Marmor MD, Skaria KB, Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58: 903-913
17. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: Receptor heterodimerization in Development and cancer. EMBO J 2000; 19: 3159-3167
18. Gu MJ, Choi JH: Clinicopathological significance of E-cadherin, '-catenin and epidermal growth factor receptor expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2012; 59: 1241-1244
19. Yoshikawa D, Ojima H, Iwasaki M, et al: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98: 418-425
20. Khan SA, Davidson BR, Goldin R, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002; 51(suppl 6):I1-I9
21. Jarnagin WR, Fong Y, DeMatteo RP, et al: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-519
22. Gores GJ: Cholangiocarcinoma: Current concepts and insights. J Hepatol 2003; 37: 961-969
23. Malhi H, Gores GJ: Cholangiocarcinoma: Modern advances in understanding a deadly old disease. J Hepatol 2006; 45: 856-867
24. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. J Gastroenterology 2005; 128: 2054-2065
25. Isomoto H: Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. J Gastroenterol 2007; 132: 384-396
26. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, et al: TGF-' suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. J Immunity 2004; 21: 491-501
27. Yamagiwa Y, Meng F, Patel T: Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. J Life Sci 2006; 78: 2494-2502
28. Werneburg NW, Yoon JH, Higuchi H, Gores GJ: Bile acids activate EGF receptor via a TGF-a-dependent mechanism in human cholangiocyte cell lines. J Physiol Gastrointest Liver Physiol 2003; 285:G31-G36
29. Yoon JH, Werneburg NW, Higuchi H, et al: Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. J Cancer Res 2002; 62: 6500-6505
30. Hwang MH, Damte D, Lee JS, et al: Mycoplasma hyopneumoniae induces pro-inflammatory cytokine and nitric oxide production through NF-?B and MAPK pathways in RAW264.7 cells. Vet Res Commun 2011; 35: 21-34
31. Han Y, Niu M, An L, Li W: Upregulation of proinflammatory cytokines and NO production in BV-Activated avian macrophage-like cell line (HD11) requires MAPK and NF-?B pathways. Int Immunopharmacol 2009; 9: 817-823
32. Chen RF, Li ZH, Kong XH, Chen JS: Effect of mutated I?Ba transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World J Gastroenterol 2005; 11: 726-728
33. Chen RF, Li ZH, Zou SQ, Chen JS: Effect of hepatitis C virus core protein on modulation of cellular proliferation and apoptosis in hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 71-74
34. Guo N, Chen R, Li Z, et al: Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 354-361
35. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4):S9-S15
36. Scoccianti C, Vesin A, Martel G, et al: Prognostic value of TP53, KRAS and EGFR mutations in non-small cell lung cancer: EUELC cohort. Eur Respir J 2012; 40: 177-184
37. Ettl T, Baader K, Stiegler C, et al: Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 2012;106:719-726
38. Woelber L, Hess S, Bohlken H, et al: EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. J Clin Pathol 2012; 65: 133-139
39. Sethi K, Sarkar S, Das S, et al: Expressions of CK-19, NF-?B, E-cadherin, '-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol 2011; 9: 187-199
40. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-1056
41. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232
42. Lee J, Park SH, Chang HM, et al: Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-Tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13: 181-188
43. Huang TW, Wang CH, Hsieh CB: Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. Onkologie 2007; 30: 129-131
44. Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, et al: MRNA expression levels and genetic status of genes involved in the EGFR and NF-?B pathways in metastatic non-small-cell lung cancer patients. J Transl Med 2011; 9: 163
45. Haussler U, von Wichert G, Schmid RM, Keller F, Schneider G: Epidermal growth factor activates nuclear factor-?B in human proximal tubule cells. Am J Physiol Renal Physiol 2005; 289:F808-F815
46. Biswas DK, Iglehart JD: Linkage between EGFR family receptors and nuclear factor-?B signaling in breast cancer. J Cell Physiol 2006; 209: 645-652
47. Habib AA, Hognason T, Ren J, Stefansson K, Ratan RR: The epidermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor ' receptor. J Biol Chem 1998; 273: 6885-6891
48. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB: Epidermal growth factor (EGF) activates nuclear factor-?B through I?Ba kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I?Ba. Oncogene 2007; 26: 7324-7332